Live
FierceBiotechInovio trims team as trouble brews at FDA for rare disease candidateFierceBiotechSana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patientFierceBiotechChina approves first brain-computer interface implant for paralyzed patients, as sector heats upEndpoints NewsGubra plots Roivant-like model as partnered obesity drugs take flightEndpoints NewsImmutep's LAG-3 drug fails Phase 3 lung cancer studyBioWorldMed14 essential for GLP-1 agonist response, study findsEndpoints NewsUltragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia diseaseBioPharma DiveEvotec, Vistagen lay off staff; Immutep shares collapse on study failureEndpoints NewsY-mAbs terminates radiopharma trial; GSK gets expanded use for ArexvyBioWorldCouncil of Scientific and Industrial Research describes anticancer agentsBioWorldOther news to note for March 13, 2026BioWorldEnodia acquires Sec61 assets from Kezar Life Sciences
Endpoints News Mar 13, 2026

Immutep's LAG-3 drug fails Phase 3 lung cancer study

Immutep's LAG-3 drug fails Phase 3 lung cancer study

Original
Body unavailable. Use the original source.

Directory

59 All